Open label, single dose study of the pharmacokinetics of tigecycline in adult subjects with primary biliary cirrhosis (PBC)
pharmacokinetic study
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Masking
NONE
Enrollment
8
Single intravenous dose of tigecycline 50 mg, as a 30-minute infusion
Pfizer Investigational Site
Saint Paul, Minnesota, United States
Pfizer Investigational Site
Durham, North Carolina, United States
Pfizer Investigational Site
Santurce, Puerto Rico, Puerto Rico
To assess the pharmacokinetics (PK) of tigecycline in subjects with cholestatic hepatic dysfunction.
Time frame: 5 days
To assess the safety and tolerability of single doses of tigecycline in subjects with cholestatic hepatic dysfunction.
Time frame: 15 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.